^
Association details:
| Biomarker: | ALK wild-type |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | Puyouheng (pucotenlimab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1458P - Pucotenlimab (HX008) - humanized anti-PD-1 monoclonal antibody plus pemetrexed and platinum as first-line treatment for advanced non-squamous non-small-cell lung cancer (nsqNSCLC): A single-arm multicenter phase II study
Published date:
10/16/2023
Excerpt:
Pucotenlimab combined with pemetrexed plus platinum demonstrated promising efficacy and safety for the 1st line nsq-NSCLC patients without EGFR/ALK mutations.
Secondary therapy:
Chemotherapy + pemetrexed
Trial ID:
